A Renal Impairment Study for PF-06651600

Status Terminated

Clinical Trial Summary

This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment (Part 2).

Clinical Trial Description

This is a Phase 1 non-randomized, open-label, parallel cohort, multi-site study to investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of PF-06651600 after multiple oral doses of 50 mg daily. Subjects will be selected and categorized into normal renal function or renal impairment groups based on their estimated glomerular filtration rate. Part 1: A total of approximately 16 subjects will be enrolled; approximately 8 subjects with severe renal impairment and approximately 8 with normal renal function. After statistical evaluation of results from Part 1, Part 2 may be conducted with approximately 8 subjects each with moderate and mild renal impairment. The total duration of participation from Screening visit to Day 11 will be a maximum of 39 days and from Screening visit to Follow-up/Contact Visit will a maximum of 73 days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04037865
Study type	Interventional
Source	Pfizer
Contact
Status	Terminated
Phase	Phase 1
Start date	August 19, 2019
Completion date	March 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01937975` - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)	Phase 1
Completed	`NCT03284164` - Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex	Phase 1
Completed	`NCT05992155` - A Study of TAK-279 in Adults With or Without Kidney Problems	Phase 1
Completed	`NCT05004311` - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics	Phase 1
Completed	`NCT04963738` - A Study of JNJ-73763989 in Adult Participants With Renal Impairment	Phase 1
Terminated	`NCT02508740` - Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment	Phase 1
Active, not recruiting	`NCT01529658` - Renal Hypothermia During Partial Nephrectomy	N/A
Terminated	`NCT00984113` - Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment	Phase 1
Completed	`NCT00750620` - A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment	Phase 1
Completed	`NCT00842868` - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases	N/A
Completed	`NCT00499187` - Fanconi Syndrome Due to ARVs in HIV-Infected Persons	Phase 4
Completed	`NCT01331941` - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function	Phase 1
Completed	`NCT05489614` - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment	Phase 1
Completed	`NCT03259087` - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)	Phase 1
Completed	`NCT05086107` - Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment	Phase 1
Recruiting	`NCT05349851` - Bowel Cleansing With Renal Impairment
Completed	`NCT03660241` - A Renal Impairment Study for PF-04965842	Phase 1
Recruiting	`NCT06037031` - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function	Phase 1
Completed	`NCT03289208` - Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment	Phase 1
Completed	`NCT02942810` - To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment	Phase 1